End Stage Renal Disease (ESRD) Drug Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
End Stage Renal Disease (ESRD) Drug Market Forecast Highlighting Growth From $171.11 Billion To $304.06 Billion
The market for end-stage renal disease (ESRD) pharmaceuticals has seen significant expansion in recent times. Its value is projected to rise from $148.55 billion in 2025 to $171.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. This past growth has been driven by several factors, including the increasing number of chronic kidney disease (CKD) cases, heightened awareness of ESRD, a growing number of dialysis facilities, improvements in kidney disease treatments, and supportive government healthcare programs.
The market for end-stage renal disease (ESRD) drugs is anticipated to experience significant expansion over the coming years, with projections indicating it will reach $304.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 15.5%. Growth during this forecast period is driven by factors such as advances in precision medicine, the increasing availability of home-based dialysis options, the incorporation of artificial intelligence into patient monitoring, heightened investment in ESRD research and development, and a rising preference for combination therapies. Key emerging trends likely to shape the future include tailored drug therapies for ESRD, home-delivered dialysis approaches, the use of telemedicine in chronic kidney disease (CKD) management, innovative drug formulations targeting secondary complications, and broader implementation of combined therapeutic regimens.
Download A Free Sample Report For Comprehensive Market Insights:
End Stage Renal Disease (ESRD) Drug Market Demand Drivers: What Is Fueling Industry Growth?
The growing prevalence of obesity and diabetes is anticipated to accelerate the expansion of the end-stage renal disease (ESRD) drug market moving forward. Obesity is defined as an abnormal or excessive accumulation of fat that presents a health risk, while diabetes is a chronic illness resulting from insufficient insulin production by the pancreas or ineffective use of the insulin that is produced. In individuals with renal disease, controlling fluid and electrolyte levels, blood pressure, and waste removal via dialysis can enhance overall health and well-being, potentially leading to weight loss and better blood sugar management. To illustrate, the World Obesity Federation, a nonprofit membership organization, predicted in 2023 that the annual global economic impact of overweight and obesity would reach US$4.32 trillion by 2035, representing nearly 3% of the world’s GDP. Additionally, data from the National Health Service, a UK government department, showed in June 2024 that 3,615,330 people registered with a general practitioner had been diagnosed with non-diabetic hyperglycemia or pre-diabetes—a condition involving elevated blood sugar levels not severe enough to be classified as diabetes—in 2023, an 18% rise compared to 3,065,825 cases in 2022. Consequently, the rising incidence of obesity and diabetes is set to drive demand for end-stage renal disease (ESRD) drugs.
End Stage Renal Disease (ESRD) Drug Market Segment Outlook: Which Categories Are Expanding The Fastest?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
End Stage Renal Disease (ESRD) Drug Market Innovation Trends: Which Developments Are Transforming The Industry?
Top corporations within the end-stage renal disease (ESRD) pharmaceutical space are prioritizing product approvals like Jardiance as a strategy to boost their market revenues. Empagliflozin is designed to assist individuals with type 2 diabetes and reduce the risk of cardiovascular complications in those with type 2 diabetes who also have heart failure or cardiovascular disease. In September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a pharmaceutical company based in the United States, secured FDA approval for Jardiance. This medication has been authorized for multiple uses, including decreasing the likelihood of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease that is at risk of deterioration, along with lowering the risk of a sustained drop in estimated glomerular filtration rate (eGFR) in adults with heart failure. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, Jardiance is not recommended for patients with type 1 diabetes or those whose eGFR measures below 20 ml/min/1.73 m.
End Stage Renal Disease (ESRD) Drug Market Key Companies And Competitive Benchmarking
Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Access The Complete End Stage Renal Disease (ESRD) Drug Market Report:
End Stage Renal Disease (ESRD) Drug Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
